Fibrotic Hypersensitivity Pneumonitis: Diagnosis and Management.
Antifibrotic treatment
Exposures
Immunosuppression
Lung fibrosis
Multidisciplinary management
UIP-like pattern
Journal
Lung
ISSN: 1432-1750
Titre abrégé: Lung
Pays: United States
ID NLM: 7701875
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
18
01
2020
accepted:
05
05
2020
pubmed:
18
5
2020
medline:
5
8
2021
entrez:
17
5
2020
Statut:
ppublish
Résumé
Fibrotic hypersensitivity pneumonitis is a complex interstitial lung disease that is not entirely understood. In its chronic and fibrotic form, hypersensitivity pneumonitis is one of the main mimickers of idiopathic pulmonary fibrosis (IPF). Distinguishing between these two conditions is challenging but is of particular clinical relevance. Two approved therapies are available for IPF, and a considerable number of clinical trials are now exploring newer pharmacological options. This impressive research effort is a consequence of new pathogenetic understanding, updated diagnostic criteria and a long history of pharmacological trials. Conversely, current knowledge gaps on pathogenesis of chronic hypersensitivity pneumonitis, coupled with lack of validated diagnostic criteria, make the management of this disease an unsolved clinical challenge. This also reflects the paucity of therapeutic clinical trials in this field. In this review, we describe the current evidence and the possible future options to approach this complex disease.
Identifiants
pubmed: 32415523
doi: 10.1007/s00408-020-00360-3
pii: 10.1007/s00408-020-00360-3
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM